More Health: For People & Animals
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education
Search
28 Result(s)
Animal Health: Our Responsibility
A champion in saving lives
How did Mexico eradicate dog-transmitted rabies - with 24 million dogs living on the street?
March 22, 2019
World Water Day - Making every drop count
Purchasing
weBuy Supplier Information
The New Source to Procure Solution for Boehringer Ingelheim based on SAP Ariba
Animal Health: Our Responsibility
Info hub: Sustainably fighting rabies
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Sites Around the World
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
More Green
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health.
More Green
More Green: Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
September 28, 2020
World Rabies Day 2020: eliminating rabies through sustainable programs
More Green
Every Drop Counts
Water Stewardship at Boehringer Ingelheim
June 17, 2019
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Fostering Science
Reimagining digital healthcare worldwide
How our digital lab BI X innovates in Ingelheim and Shanghai
Animal Health Innovation
Supporting future veterinarians
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
June 28, 2021
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
March 12, 2020
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease
May 21, 2021
Positive CHMP opinion for a heart failure indication
June 21, 2021
Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
July 06, 2021
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
July 30, 2020
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
November 18, 2020
New: Empagliflozin reduced risk of recurrent CV events
August 27, 2021
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
November 06, 2021